Gavreto is a preferred first-line treatment for metastatic RET fusion-positive NSCLC, with FDA approval based on the ARROW study and potential severe side effects. For patients diagnosed with RET fusion-positive, metastatic non-small cell lung cancer (NSCLC), understanding treatment options is […]
Gavreto in First-Line RET Fusion NSCLC Read More »
Elevation Oncology discontinues EO-3021 for gastric and GEJ cancers after phase 1 trial shows insufficient efficacy, focusing on advancing EO-1022 instead. Elevation Oncology announced that it has elected to discontinue development of EO-3021, an antibody-drug conjugate (ADC), which was being
Development of EO-3021 Discontinued for Gastric and GEJ Cancers Read More »
Gene expression testing helps determine the necessity of chemotherapy in hormone receptor-positive breast cancer, optimizing treatment and minimizing unnecessary toxicity. Breast cancer treatment continues to evolve with advancements in gene expression testing and targeted therapies, helping to refine treatment decisions
Gene Expression Testing and Targeted Therapies in Breast Cancer Care Read More »
The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression. The U.S. Food and Drug Administration (FDA) has granted traditional approval to treatment with Keytruda (pembrolizumab) plus Herceptin (trastuzumab) and fluoropyrimidine- and platinum-containing chemotherapy
FDA Approves Keytruda in HER2+ Gastric, Gastroesophageal Junction Cancer Read More »
Genetic and genomic testing are key in breast cancer risk and treatment, with Dr. Mark Robson explaining their evolving roles at the Miami Breast Cancer Summit. Genetic and genomic testing play a critical role in understanding breast cancer risk and
Understanding Genetic and Genomic Testing in Breast Cancer Read More »
Orca-T improved survival free of moderate-to-severe cGVHD across leukemia subtypes: © nobeastsofierce – stock.adobe.com. Orca-T, a T-cell immunotherapy, significantly improved survival free of moderate-to-severe chronic graft-versus-host disease (cGvHD) compared with allogeneic hematopoietic stem cell transplant (alloHSCT) in the phase 3
Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia Read More »
Elahere shows consistent survival benefits in patients with folate receptor alpha-positive platinum-resistant ovarian cancer: ©mi_viri – stock.adobe.com. Treatment with Elahere (mirvetuximab soravtansine-gynx) showed consistent survival benefits in a long-term analysis from the phase 3 trial MIRASOL evaluating patients with folate
Elahere Shows Consistent Survival Benefit in Ovarian Cancer Subset Read More »
The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer: © Crystal Light – stock.adobe.com. The Food and Drug Administration (FDA) has granted orphan drug designation to PEP-010 — a first-in-class bifunctional therapeutic peptide — for the treatment
FDA Grants Orphan Drug Designation to PEP-010 in Pancreatic Cancer Read More »
Jakafi shows limited long-term benefits in CALR-mutated myelofibrosis, with patients requiring more targeted therapies for better outcomes, according to real-world data. Among patients with calreticulin (CALR)-mutated myelofibrosis, real-world data reveal insights into those with splenomegaly and/or symptoms requiring therapy with
Jakafi May Not Associate with Long-Term Benefits in Myelofibrosis Subset Read More »
Following the BCG shortage, the first patient with bladder cancer has been dosed with rBCG in the U.S. © freshidea – stock.adobe.com The first patients with bladder cancer has been dosed with recombinant Bacillus Calmette-Guérin (rBCG) following the current shortage
First Patient Dosed With Recombinant Bacillus Calmette-Guérin in Bladder Cancer Read More »
